{"id":902486,"date":"2025-10-29T18:28:53","date_gmt":"2025-10-29T22:28:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/"},"modified":"2025-10-29T18:28:53","modified_gmt":"2025-10-29T22:28:53","slug":"revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/","title":{"rendered":"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025"},"content":{"rendered":"
\n

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.<\/p>\n

To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations<\/a>. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days.<\/p>\n

\n About Revolution Medicines, Inc.<\/strong>
\n
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company\u2019s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company\u2019s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company\u2019s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

\n Revolution Medicines Media & Investor Contact:<\/strong>
\n
media@revmed.com
investors@revmed.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. About Revolution Medicines, Inc. Revolution … <\/p>\n

Continue reading “Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-902486","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. About Revolution Medicines, Inc. Revolution … Continue reading "Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T22:28:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025\",\"datePublished\":\"2025-10-29T22:28:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/\",\"name\":\"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=\",\"datePublished\":\"2025-10-29T22:28:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. About Revolution Medicines, Inc. Revolution … Continue reading \"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-29T22:28:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025","datePublished":"2025-10-29T22:28:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/"},"wordCount":273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/","name":"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=","datePublished":"2025-10-29T22:28:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Mzk0NiM3MjI5NTYwIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2025-after-market-close-on-november-5-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/902486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=902486"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/902486\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=902486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=902486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=902486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}